Skip to content

19-459 - S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)

Status: open

S1400F: Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Treatment for stage IV lung cancer that has come back

Contact Us Or call (251) 445-9834

Description

This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread

Sponsors

This trial is sponsored by National Cancer Institute (NCI).

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.